Waters Corp. Updates Instruments and Software - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Waters Corp. Updates Instruments and Software


At Pittcon 2013 in Philadelphia, Waters Corp. announced improvement to chromatography systems and software.

The company reported enhancements to the Waters Alliance HPLC system that will maintain key Alliance performance specifications and control algorithms to ensure that analysts can replicate their existing methods. The system features updated electronics and user interface. The updated systems can be used with Waters eXtended Performance [XP], 2.5 μm columns.

The company also announced an expansion of its laboratory informatics offerings, with the addition of Paradigm Scientific Search Software, which allows users to perform object-based searches across both structured and unstructured data and across different data platforms.

Mobile access and new laboratory analytics enhancements were added to Empower 3 chromatography data software.

Quality Control Reference Materials (QCRMs) and Certified Containers for Waters instruments were added to the Analytical Standards and Reagents product group.

Another technology introduction is the Waters ACQUITY Advanced Polymer Chromatography (APC) System, the company says, defines a new category of chromatographic polymer analysis, yielding improved molecular weight information about polymeric species, faster than ever before.

Waters Corp. announced updates to the Alliance HPLC system and Empower 3 chromatography data software, and introduced search software and reference materials.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here